On April 16, 2026 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, reported a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NOX-A12 + radiotherapy + anti-VEGF "triple therapy" in glioblastoma patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The article in the scientific peer-reviewed high-impact journal, Nature Communications, describes results of the expansion cohort Arm A in TME Pharma’s Phase 1/2 GLORIA trial. In this arm, chemotherapy-resistant (MGMT unmethylated) glioblastoma patients with residual tumor after surgery received NOX-A12 + radiotherapy + anti-VEGF (bevacizumab) "Triple Therapy". The authors noted that overall survival (OS) of patients receiving NOX-A12 Triple Therapy significantly outperformed two different cohorts of similar patients external to the trial who received standard of care treatment, and further noted that due to the conservative trial design, the study "likely underestimates survival compared with most contemporary trials."

As already disclosed in the March 5, 2024 press release, the GLORIA trial has been amended to allow inclusion of 100 additional patients in a randomized, controlled Phase 2 part of the trial composed of 5 additional arms (Expansion Group Arms D through H) to assess three different doses of NOX-A12 in the Triple Therapy, one dose of NOX-A12 + radiotherapy and standard of care. It is planned to initiate this Phase 2 part of the trial once appropriate partnerships are in place.

The findings described in the publication demonstrate the potential and value of TME Pharma’s NOX-A12 asset. TME Pharma remains confident in its strategy to search for a strategic partner to outlicense NOX-A12with the goal of bringing NOX-A12 to market authorization. As communicated on January 5, 2026, TME Pharma continues its active discussions with potential partners for the NOX-A12 program.

As indicated in its press release of March 9, 2026, TME Pharma’s financial runway now extends to Q2-2027, providing the company with the flexibility to identify the optimal partnership for NOX-A12.

Diede van den Ouden, CEO of TME Pharma, said: "We are encouraged by the publication in Nature Communications, which underscore the scientific validity of our approach. We remain fully committed to bringing NOX-A12 to success and believe that a strategic partnership is the optimal path forward. With our extended cash runway, we are well-positioned to continue our negotiations with potential partners."

(Press release, TME Pharma, APR 16, 2026, View Source [SID1234664460])

On April 16, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, encouraging Phase 2 clinical signals, and a rapidly strengthening global regulatory and intellectual property ("IP") position.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The initiation of Phase 3 planning marks a critical step forward in our mission to bring Ampligen to patients with pancreatic cancer," said Thomas K. Equels, Chief Executive Officer of AIM. "With a growing body of positive late-stage pancreatic ductal adenocarcinoma clinical data, more than 100 subjects treated, Orphan Drug Designations in the U.S. and EU, and a strong global IP portfolio, we believe Ampligen has the potential to be a game-changing therapy in one of the most lethal cancers and a significant driver of long-term stockholder value."

The Company recently announced a strategic agreement with the PPD clinical research business of Thermo Fisher Scientific to design its planned Phase 3 clinical trial of Ampligen in late-stage pancreatic cancer. This collaboration brings world-class clinical development expertise to support trial design and positions AIM to efficiently advance Ampligen into late-stage development.

The planned Phase 3 program is supported by very positive published data from a Dutch government-approved Named Patient Program ("NPP") with Ampligen as a monotherapy in late-stage pancreatic ductal adenocarcinoma and reported encouraging data from the ongoing Phase 2 DURIPANC study, which is evaluating Ampligen in combination with AstraZeneca’s durvalumab. That ongoing study is showing promising improvement in progression-free survival and overall survival, as well as a favorable safety profile. Conducted in collaboration with AstraZeneca and Erasmus Medical Center, the study is expected to complete enrollment later this year and represents a key clinical validation step for our upcoming pivotal trial. As mentioned above, similar positive data was observed in the NPP, where Ampligen as a monotherapy was administered to 82 total patients and which had a significant positive findings on both progression-free and overall survival compared to historical controls. We believe these extremely positive data help to de-risk the path forward.

Pancreatic cancer represents a large and rapidly growing global market opportunity, with incidence rising and limited innovation over several decades. It is projected to become the second leading cause of cancer-related deaths in the United States, underscoring both the urgency and the commercial potential for new therapeutic options.

Ampligen, a selective TLR3 agonist, is designed to activate innate immunity and improve tumor responsiveness, making it a strong candidate for use as both a monotherapy and in combination with checkpoint inhibitors in multiple solid tumor types, and specifically with positive Phase 1/2 safety and efficacy data in combination with AstraZeneca’s durvalumab and Merck’s pembrolizumab in pancreatic cancer.

The Company continues to expand its global IP portfolio. AIM recently obtained final approval of a Japanese patent covering Ampligen in combination with checkpoint inhibitors, which is set to expire in 2039. Existing patents in the United States and Europe also extend to 2039, with broad claims supporting combination use across multiple oncology indications. This IP estate positions Ampligen for long-term commercial protection across major markets.

AIM’s IP portfolio includes orphan drug designations for pancreatic cancer in both the United States and Europe, and the Company announced in March 2026 that it would seek similar status in Japan. The United States, Europe and Japan are the three largest accessible pharma markets in the world – and pancreatic cancer is potentially one of the most lucrative global health markets, as it is a serious and unmet need that is expected to become an even greater health burden. These designations provide potential market exclusivity upon approval, regulatory incentives, reduced development costs, and opportunities for accelerated development pathways, reinforcing the Company’s strategy and enhancing long-term value creation.

Looking ahead, AIM anticipates several near-term milestones that may serve as significant value drivers. These include the completion of Phase 2 DURIPANC enrollment and additional data updates; continued clinical data readouts; further IP expansion and regulatory progress; the potential for new developments from existing strategic collaborations; and the design, IND approval and commencement of a Phase 3 pivotal study in pancreatic cancer.

As previously announced, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event today, April 16, 2026 at 4:00 PM ET. A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.

(Press release, AIM ImmunoTech, APR 16, 2026, View Source [SID1234664429])

On April 16, 2026 Elephas Biosciences Corporation (Elephas), a private company that has developed the elive ex vivo tumor profiling platform, reported a scientific collaboration with Mithrl, an AI company focused on accelerating research through its Scientific Decision Engine (SDE). Combining these innovative approaches establishes a foundation for integrating functional tumor profiling with AI-driven analysis to support more scalable and systematic discovery of novel immunotherapy response signals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Elephas elive platform captures real-time cytokine responses from live tumor fragments of core needle biopsies. Pairing the elive platform with Mithrl’s SDE enables autonomous design and execution of multi-step scientific analyses under rigorous controls.

Along with Mithrl, Elephas will be co-presenting new data from this collaboration at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, highlighting the potential of combining real-time functional tumor profiling with multi-modal data analysis to generate biologically meaningful insights more efficiently.

Poster Presentation: Multi-agent-augmented analysis of PD-1 checkpoint inhibitor response (Abstract #5695)
Date/Time: April 20, 2026, 9:00 AM – 12:00 PM PST
Location: Section 40

Learn more on the poster here: View Source!/21436/presentation/9781

"Partnering with Mithrl enables us to more fully leverage the richness of our functional profiling data and showcase the power of Agentic AI," said Hinco Gierman, CSO of Elephas. "By integrating these data with external datasets, we’re incredibly impressed with the speed at which Mithrl is able to generate novel insights that can better understand the biology of response and generate insights that may help guide translational research and therapeutic development."

"Collaborating with Elephas allows us to pair their unprecedented real-time tumor profiling from live tumor biopsies with Mithrl’s SDE to unlock deep biological insights that would otherwise remain elusive or take months to surface. I believe this combination exemplifies the future of translational research," said Vivek Adarsh, Co-Founder and CEO of Mithrl.

(Press release, Elephas Biosciences, APR 16, 2026, View Source [SID1234664445])

On April 16, 2026 STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, reported a successful $56 million Series C financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3, including funding the Company’s Phase 2 monotherapy study in selected sarcoma indications, in which the first patient has now been successfully dosed. Sarcoma is a form of cancer that arises in bone or soft tissues, including muscle, fat, cartilage, blood vessels, and other connective or supportive tissue. This study is designed to support a potential accelerated regulatory approval pathway for STC-15 and to establish a foundation for subsequent clinical development across additional oncology indications.

STC-15 inhibits METTL3, an RNA-modifying enzyme involved in the regulation of cancer stem cell differentiation, a critical process in the development of sarcomas and other malignancies. In a Phase 1 monotherapy study, STC-15 demonstrated durable tumor regression across multiple sarcoma subtypes, underscoring its potential to target and reprogram progenitor cells that transform into cancer cells. These results will be presented at an upcoming medical conference in 2026.

Jerry McMahon, Chief Executive Officer of STORM Therapeutics, said: "Advancing our first‑in‑class METTL3 inhibitor, STC-15, into Phase 2 clinical development marks a pivotal breakthrough in tackling cancers characterized by aberrant cell differentiation. This milestone highlights our scientific innovation and the potential to create new therapeutic options for patients with substantial unmet needs. We are grateful for the steadfast support from our investors and are encouraged by the robust durability and activity demonstrated with STC-15 in Phase 1 studies. As we begin our Phase 2 trial, our focus remains on addressing critical unmet needs in sarcoma for the benefit of patients."

Jonathan Trent, MD of the University of Miami, Sylvester Comprehensive Cancer Center, commented: "The launch of the Phase 2 trial for STC-15 represents a significant advancement in the treatment landscape for sarcoma and other tumors driven by METTL3. STC-15’s novel mechanism of action targets sarcomas at their vulnerability, reprogramming malignant cells toward cell cycle arrest and apoptosis. We are hopeful that this research will yield meaningful insights and, ultimately, new therapeutic avenues for patients with pressing unmet needs."

STORM’s sarcoma program builds on previous clinical and translational research in epitranscriptomic regulation, emphasizing the importance of RNA-modifying enzymes in the maintenance of stem cell‑derived tumors and their potential application in broader settings. METTL3 methylates mRNA, influencing the differentiation processes of connective tissues and other cell types. Sarcomas arise from transformed mesenchymal stem cells as they progress into malignant connective tissue cells, accounting for 1% of adult cancers and 15% of pediatric cancers. Due to the frequent absence of driver mutations or immunogenic features amenable to standard treatments, sarcomas depend on METTL3-driven methylation for growth and survival. The Phase 2 trial will assess the anti-tumor effects of inhibiting mRNA methylation in sarcomas.

The financing was funded by existing investors, M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, the UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), and Fast Track Initiative (FTI).

(Press release, STORM Therapeutics, APR 16, 2026, View Source [SID1234664461])

On April 16, 2026 Allogene Therapeutics, Inc. (Nasdaq: ALLO) reported the closing of its previously reported underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. In addition, the underwriters partially exercised their option and purchased 12,700,000 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from this offering were $200.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures.

Goldman Sachs & Co. LLC, Jefferies and TD Cowen acted as joint bookrunners for the offering. Piper Sandler and William Blair also acted as joint bookrunners for the offering. Baird and Canaccord Genuity acted as lead managers for the offering. TPG Capital BD, LLC acted as co-manager for the offering.

The shares of common stock described above were offered by Allogene pursuant to a shelf registration statement filed by Allogene with the Securities and Exchange Commission (SEC) that was declared effective on April 25, 2024. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website located at View Source Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at [email protected]; or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by emailing [email protected]; or from TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Allogene, APR 16, 2026, View Source [SID1234664430])